Teva Pharmaceutical Statistics
Total Valuation
Teva Pharmaceutical has a market cap or net worth of $22.50 billion. The enterprise value is $37.88 billion.
Important Dates
The next confirmed earnings date is Wednesday, November 5, 2025, before market open.
| Earnings Date | Nov 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Teva Pharmaceutical has 1.15 billion shares outstanding. The number of shares has increased by 1.25% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.15B |
| Shares Change (YoY) | +1.25% |
| Shares Change (QoQ) | +0.17% |
| Owned by Insiders (%) | 0.42% |
| Owned by Institutions (%) | 78.93% |
| Float | 1.14B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 7.50 |
| PS Ratio | 1.34 |
| Forward PS | 1.31 |
| PB Ratio | 3.30 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 25.28 |
| P/OCF Ratio | 16.18 |
| PEG Ratio | 1.02 |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 8.38, with an EV/FCF ratio of 42.56.
| EV / Earnings | n/a |
| EV / Sales | 2.28 |
| EV / EBITDA | 8.38 |
| EV / EBIT | 10.82 |
| EV / FCF | 42.56 |
Financial Position
The company has a current ratio of 1.06, with a Debt / Equity ratio of 2.57.
| Current Ratio | 1.06 |
| Quick Ratio | 0.48 |
| Debt / Equity | 2.57 |
| Debt / EBITDA | 3.76 |
| Debt / FCF | 19.71 |
| Interest Coverage | 3.59 |
Financial Efficiency
Return on equity (ROE) is -2.42% and return on invested capital (ROIC) is 8.77%.
| Return on Equity (ROE) | -2.42% |
| Return on Assets (ROA) | 5.37% |
| Return on Invested Capital (ROIC) | 8.77% |
| Return on Capital Employed (ROCE) | 12.38% |
| Revenue Per Employee | $451,480 |
| Profits Per Employee | -$4,263 |
| Employee Count | 36,830 |
| Asset Turnover | 0.41 |
| Inventory Turnover | 2.26 |
Taxes
In the past 12 months, Teva Pharmaceutical has paid $94.00 million in taxes.
| Income Tax | 94.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +9.55% in the last 52 weeks. The beta is 0.71, so Teva Pharmaceutical's price volatility has been lower than the market average.
| Beta (5Y) | 0.71 |
| 52-Week Price Change | +9.55% |
| 50-Day Moving Average | 19.10 |
| 200-Day Moving Average | 17.32 |
| Relative Strength Index (RSI) | 54.31 |
| Average Volume (20 Days) | 9,007,672 |
Short Selling Information
| Short Interest | 47.28M |
| Short Previous Month | 55.19M |
| Short % of Shares Out | 4.14% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 4.64 |
Income Statement
In the last 12 months, Teva Pharmaceutical had revenue of $16.63 billion and -$157.00 million in losses. Loss per share was -$0.14.
| Revenue | 16.63B |
| Gross Profit | 8.25B |
| Operating Income | 3.50B |
| Pretax Income | -68.00M |
| Net Income | -157.00M |
| EBITDA | 4.52B |
| EBIT | 3.50B |
| Loss Per Share | -$0.14 |
Full Income StatementBalance Sheet
The company has $2.16 billion in cash and $17.54 billion in debt, giving a net cash position of -$15.38 billion or -$13.41 per share.
| Cash & Cash Equivalents | 2.16B |
| Total Debt | 17.54B |
| Net Cash | -15.38B |
| Net Cash Per Share | -$13.41 |
| Equity (Book Value) | 6.83B |
| Book Value Per Share | 5.95 |
| Working Capital | 759.00M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $1.39 billion and capital expenditures -$500.00 million, giving a free cash flow of $890.00 million.
| Operating Cash Flow | 1.39B |
| Capital Expenditures | -500.00M |
| Free Cash Flow | 890.00M |
| FCF Per Share | $0.78 |
Full Cash Flow StatementMargins
Gross margin is 49.60%, with operating and profit margins of 21.05% and -0.94%.
| Gross Margin | 49.60% |
| Operating Margin | 21.05% |
| Pretax Margin | -0.41% |
| Profit Margin | -0.94% |
| EBITDA Margin | 27.20% |
| EBIT Margin | 21.05% |
| FCF Margin | 5.35% |
Dividends & Yields
Teva Pharmaceutical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.25% |
| Shareholder Yield | -1.25% |
| Earnings Yield | -0.70% |
| FCF Yield | 3.96% |
Dividend DetailsAnalyst Forecast
The average price target for Teva Pharmaceutical is $25.57, which is 30.39% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $25.57 |
| Price Target Difference | 30.39% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 1, 2004. It was a forward split with a ratio of 2:1.
| Last Split Date | Jul 1, 2004 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Teva Pharmaceutical has an Altman Z-Score of 0.57 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.57 |
| Piotroski F-Score | 6 |
